

Hepatitis Testing/Diagnosis Market by Disease Type (Hepatitis B, Hepatitis C, Other Hepatitis), Technology (ELISA, RDT, PCR, INAAT), End User (Hospitals, Diagnostic Laboratories, Blood Banks), and Region - Global Forecast to 2026

<https://marketpublishers.com/r/H234F687B2EEN.html>

Date: November 2021

Pages: 175

Price: US\$ 4,950.00 (Single User License)

ID: H234F687B2EEN

Abstracts

The global hepatitis testing market is projected to reach USD 3.6 billion by 2026 from USD 2.8 billion in 2021, at a CAGR of 4.7% during the forecast period. The growth of the global hepatitis testing market is being driven by factors such as the high burden of hepatitis, increasing blood transfusion and donations, benefits of POC instruments and kits, and awareness initiatives on hepatitis. High cost of nucleic acid tests, lack of mandates for nucleic acid tests in developing countries and unfavorable reimbursement scenarios are expected to restrain hepatitis market growth. Emerging markets, rising technological advancements in molecular diagnostics, and growth in the biotechnology and biopharmaceutical industries are expected to offer strong growth opportunities for players in the market. In contrast, changing regulatory landscape, operational barriers and shortage of skilled professionals may challenge market growth to a certain extent. The hepatitis testing market is segmented based on disease type, technology, end user, and region.

“Hepatitis B segment is expected to dominate the market during the forecast period.”

Based on disease type, the hepatitis testing market is segmented into hepatitis B, hepatitis C, and other hepatitis diseases (hepatitis A, D, and E). The hepatitis B segment accounted for the largest share of the hepatitis testing market in 2020. Factors such as the rising prevalence of hepatitis B, availability of a large number of hepatitis B diagnostic tests, and the increasing adoption of nucleic acid tests for HBV diagnosis are driving the growth of this market segment.

“ELISA segment holds highest market share during the forecast period.”

Based on technology, the hepatitis testing market is segmented into enzyme-linked immunosorbent assay (ELISA), rapid diagnostic tests, polymerase chain reaction (PCR), isothermal nucleic acid amplification technology (INAAT), and other technologies (such as sequencing, mass spectrometry, and western blotting). The ELISA segment accounted for the largest share of the hepatitis testing market in 2020. The large share of this segment can primarily be attributed to the wide acceptance of this test in clinical practices to diagnose hepatitis.

“Hospital & Diagnostic Laboratories segment to dominate the market during the forecast period.”

Based on end user, the hepatitis testing market is segmented into hospital & diagnostic laboratories, blood banks, and other end users (academic & government research institutes, nursing homes, and home care settings). In 2020, the hospital & diagnostic laboratories segment accounted for the largest share of the hepatitis testing market. The large share of this segment can be attributed to the large number of hepatitis diagnostic tests carried out in hospitals.

“North America will dominate the market during the forecast period.”

The global hepatitis testing market is segmented into North America (the US and Canada), Europe (Germany, the UK, and the Rest of Europe), Asia Pacific, and Rest of the World. In 2020, North America dominates the global market, and this trend is expected to continue during the forecast period. The large share and high growth of this region can be attributed to the rising prevalence of hepatitis and increased research and clinical trials for hepatitis testing in the US.

The primary interviews conducted for this report can be categorized as follows:

By Company Type -Tier 1: 32%,Tier 2: 42% and Tier 26%

By Designation - C-level:23%, D-level:35%, and Others:42%

By Region - North America:39%, Europe:25%, Asia Pacific:26%, and Rest of the World: 10%

List of Companies Profiled in the Report

F. Hoffmann-La Roche Ltd. (Switzerland)

Abbott Laboratories (US)

Siemens Healthineers AG (Germany)

Bio-Rad Laboratories, Inc. (US)

Danaher Corporation (US)

QIAGEN (Netherlands)

bioMérieux SA (France)

DiaSorin S.P.A. (Italy)

Ortho Clinical Diagnostics (US)

MedMira Inc. (Canada)

Fujirebio US, Inc. (Japan)

Grifols, S.A. (Spain)

Orasure Technologies (US)

GenMark Diagnostics Inc. (US)

Vela Diagnostics (Singapore)

Epitope Diagnostics (US)

Trivitron Healthcare (India)

Meril Life Sciences Pvt. Ltd. (India)

geneOmbio Technologies Pvt. Ltd. (India)

Molbio Diagnostics Pvt. Ltd. (India)

Research Coverage:

This report provides a detailed picture of the global hepatitis testing market. It aims at estimating the size and future growth potential of the market across different segments, such as disease type, technology, end user and region. The report also analyzes factors (such as drivers, restraints, opportunities and challenges) affecting market growth. It evaluates the opportunities in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micromarkets with respect to their growth trends, prospects, and contributions to the total hepatitis testing market. The report forecasts the revenue of the market segments with respect to four major regions.

Reasons to Buy the Report:

The report provides insights on the following pointers:

Market Penetration: Comprehensive information on hepatitis testing offered by the top 20 players in the hepatitis testing market. The report analyses the hepatitis testing market by disease type, technology, end user and region.

Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various hepatitis testing across key geographic regions.

Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the hepatitis testing market.

Competitive Assessment: In-depth assessment of market ranking and strategies of the leading players in the hepatitis testing market.

Contents

1 INTRODUCTION

- 1.1 OBJECTIVES OF THE STUDY
- 1.2 MARKET DEFINITION
 - 1.2.1 INCLUSIONS & EXCLUSIONS OF THE STUDY
- 1.3 MARKET SCOPE
 - FIGURE 1 HEPATITIS TESTING MARKET SEGMENTATION
 - 1.3.1 YEARS CONSIDERED FOR THE STUDY
- 1.4 CURRENCY
- 1.5 STAKEHOLDERS
- 1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

- 2.1 RESEARCH DATA
 - FIGURE 2 RESEARCH DESIGN
 - 2.1.1 SECONDARY DATA
 - 2.1.1.1 Secondary sources
 - 2.1.2 PRIMARY DATA
 - FIGURE 3 PRIMARY SOURCES
 - 2.1.2.1 Key industry insights
 - FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
- 2.2 MARKET SIZE ESTIMATION
 - FIGURE 5 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH
 - 2.2.1 GROWTH FORECAST
 - FIGURE 6 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
 - FIGURE 7 TOP-DOWN APPROACH
- 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
 - FIGURE 8 DATA TRIANGULATION METHODOLOGY
- 2.4 MARKET SHARE ANALYSIS
- 2.5 ASSUMPTIONS FOR THE STUDY
 - 2.5.1 COVID-19-SPECIFIC ASSUMPTIONS
- 2.6 LIMITATIONS
- 2.7 RISK ASSESSMENT
- 2.8 COVID-19 ECONOMIC ASSESSMENT
- 2.9 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO

FIGURE 9 CRITERIA IMPACTING THE GLOBAL ECONOMY

FIGURE 10 RECOVERY SCENARIO OF THE GLOBAL ECONOMY

3 EXECUTIVE SUMMARY

FIGURE 11 HEPATITIS TESTING MARKET, BY DISEASE TYPE, 2021 VS. 2026 (USD MILLION)

FIGURE 12 HEPATITIS TESTING MARKET, BY TECHNOLOGY, 2021 VS. 2026 (USD MILLION)

FIGURE 13 HEPATITIS TESTING MARKET, BY END USER, 2021 VS. 2026 (USD MILLION)

FIGURE 14 HEPATITIS TESTING MARKET, BY REGION, 2021 VS. 2026 (USD MILLION)

4 PREMIUM INSIGHTS

4.1 HEPATITIS TESTING MARKET OVERVIEW

FIGURE 15 HIGH BURDEN OF HEPATITIS TO DRIVE MARKET GROWTH

4.2 HEPATITIS TESTING MARKET, BY TECHNOLOGY (2021–2026)

FIGURE 16 RAPID DIAGNOSTIC TESTS SEGMENT TO REGISTER THE HIGHEST CAGR DURING THE FORECAST PERIOD

4.3 NORTH AMERICA: HEPATITIS TESTING MARKET, BY DISEASE TYPE AND COUNTRY (2020)

FIGURE 17 THE US ACCOUNTED FOR THE LARGEST SHARE OF THE NORTH AMERICAN HEPATITIS TESTING MARKET IN 2020

4.4 HEPATITIS TESTING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

FIGURE 18 ASIA PACIFIC TO REGISTER THE HIGHEST GROWTH DURING THE FORECAST PERIOD

5 MARKET OVERVIEW

5.1 INTRODUCTION

FIGURE 19 HEPATITIS TESTING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES

5.2 MARKET DYNAMICS

5.2.1 DRIVERS

5.2.1.1 High burden of hepatitis

TABLE 1 HEPATITIS PREVALENCE, BY REGION, 2019 (MILLION)

5.2.1.2 Increasing blood transfusion and donations

TABLE 2 AVERAGE PREVALENCE OF HEPATITIS INFECTION IN BLOOD DONATIONS, BY INCOME GROUP

5.2.1.3 Benefits of POC instruments and kits

5.2.1.4 Awareness initiatives on hepatitis

5.2.2 RESTRAINTS

5.2.2.1 High cost of nucleic acid tests

5.2.2.2 Lack of mandates for nucleic acid tests in developing countries

5.2.2.3 Unfavorable reimbursement scenario

5.2.3 OPPORTUNITIES

5.2.3.1 Emerging markets

5.2.3.2 Rising technological advancements in molecular diagnostics

5.2.3.3 Growth in the biotechnology and biopharmaceutical industries

5.2.4 CHALLENGES

5.2.4.1 Changing regulatory landscape

5.2.4.2 Operational barriers

5.2.4.3 Shortage of skilled professionals

5.3 COVID-19 IMPACT ON THE HEPATITIS TESTING MARKET

6 HEPATITIS TESTING MARKET, BY DISEASE TYPE

6.1 INTRODUCTION

TABLE 3 HEPATITIS TESTING MARKET, BY DISEASE TYPE, 2018–2020 (USD MILLION)

TABLE 4 HEPATITIS TESTING MARKET, BY DISEASE TYPE, 2021–2026 (USD MILLION)

6.2 HEPATITIS B (HBV)

6.2.1 HEPATITIS B SEGMENT TO HOLD THE LARGEST MARKET SHARE DURING THE FORECAST PERIOD

TABLE 5 HEPATITIS B CHRONIC INFECTIONS IN THE WESTERN PACIFIC REGION, 2019

TABLE 6 HEPATITIS B TESTING MARKET, BY REGION, 2018–2020 (USD MILLION)

TABLE 7 HEPATITIS B TESTING MARKET, BY REGION, 2021–2026 (USD MILLION)

TABLE 8 NORTH AMERICA: HEPATITIS B TESTING MARKET, BY COUNTRY, 2018–2020 (USD MILLION)

TABLE 9 NORTH AMERICA: HEPATITIS B TESTING MARKET, BY COUNTRY, 2021–2026 (USD MILLION)

TABLE 10 EUROPE: HEPATITIS B TESTING MARKET, BY COUNTRY, 2018–2020 (USD MILLION)

TABLE 11 EUROPE: HEPATITIS B TESTING MARKET, BY COUNTRY, 2021–2026

(USD MILLION)

6.3 HEPATITIS C (HCV)

6.3.1 GOVERNMENT INITIATIVES FOR SUPPORTING HCV DIAGNOSIS TO DRIVE MARKET GROWTH

TABLE 12 HEPATITIS C CHRONIC INFECTIONS IN THE WESTERN PACIFIC REGION, 2019

TABLE 13 HEPATITIS C TESTING MARKET, BY REGION, 2018–2020 (USD MILLION)

TABLE 14 HEPATITIS C TESTING MARKET, BY REGION, 2021–2026 (USD MILLION)

TABLE 15 NORTH AMERICA: HEPATITIS C TESTING MARKET, BY COUNTRY, 2018–2020 (USD MILLION)

TABLE 16 NORTH AMERICA: HEPATITIS C TESTING MARKET, BY COUNTRY, 2021–2026 (USD MILLION)

TABLE 17 EUROPE: HEPATITIS C TESTING MARKET, BY COUNTRY, 2018–2020 (USD MILLION)

TABLE 18 EUROPE: HEPATITIS C TESTING MARKET, BY COUNTRY, 2021–2026 (USD MILLION)

6.4 OTHER HEPATITIS DISEASES

TABLE 19 REPORTED HEPATITIS A CASES IN THE US SINCE 2016

TABLE 20 OTHER HEPATITIS DISEASE TESTING MARKET, BY REGION, 2018–2020 (USD MILLION)

TABLE 21 OTHER HEPATITIS DISEASE TESTING MARKET, BY REGION, 2021–2026 (USD MILLION)

TABLE 22 NORTH AMERICA: OTHER HEPATITIS DISEASE TESTING MARKET, BY COUNTRY, 2018–2020 (USD MILLION)

TABLE 23 NORTH AMERICA: OTHER HEPATITIS DISEASE TESTING MARKET, BY COUNTRY, 2021–2026 (USD MILLION)

TABLE 24 EUROPE: OTHER HEPATITIS DISEASE TESTING MARKET, BY COUNTRY, 2018–2020 (USD MILLION)

TABLE 25 EUROPE: OTHER HEPATITIS DISEASE TESTING MARKET, BY COUNTRY, 2021–2026 (USD MILLION)

7 HEPATITIS TESTING MARKET, BY TECHNOLOGY

7.1 INTRODUCTION

TABLE 26 HEPATITIS TESTING MARKET, BY TECHNOLOGY, 2018–2020 (USD MILLION)

TABLE 27 HEPATITIS TESTING MARKET, BY TECHNOLOGY, 2021–2026 (USD

MILLION)

7.2 ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA)

7.2.1 ELISA IS WIDELY USED FOR THE DETECTION OF HEPATITIS

TABLE 28 HEPATITIS TESTING MARKET FOR ELISA, BY REGION, 2018–2020 (USD MILLION)

TABLE 29 HEPATITIS TESTING MARKET FOR ELISA, BY REGION, 2021–2026 (USD MILLION)

TABLE 30 NORTH AMERICA: HEPATITIS TESTING MARKET FOR ELISA, BY COUNTRY, 2018–2020 (USD MILLION)

TABLE 31 NORTH AMERICA: HEPATITIS TESTING MARKET FOR ELISA, BY COUNTRY, 2021–2026 (USD MILLION)

TABLE 32 EUROPE: HEPATITIS TESTING MARKET FOR ELISA, BY COUNTRY, 2018–2020 (USD MILLION)

TABLE 33 EUROPE: HEPATITIS TESTING MARKET FOR ELISA, BY COUNTRY, 2021–2026 (USD MILLION)

7.3 RAPID DIAGNOSTIC TESTS (RDT)

7.3.1 RAPID TESTS ARE HIGHLY USEFUL IN COUNTRIES WITH LIMITED ACCESSIBILITY TO SOPHISTICATED TECHNOLOGIES

TABLE 34 HEPATITIS TESTING MARKET FOR RAPID DIAGNOSTIC TESTS, BY REGION, 2018–2020 (USD MILLION)

TABLE 35 HEPATITIS TESTING MARKET FOR RAPID DIAGNOSTIC TESTS, BY REGION, 2021–2026 (USD MILLION)

TABLE 36 NORTH AMERICA: HEPATITIS TESTING MARKET FOR RAPID DIAGNOSTIC TESTS, BY COUNTRY, 2018–2020 (USD MILLION)

TABLE 37 NORTH AMERICA: HEPATITIS TESTING MARKET FOR RAPID DIAGNOSTIC TESTS, BY COUNTRY, 2021–2026 (USD MILLION)

TABLE 38 EUROPE: HEPATITIS TESTING MARKET FOR RAPID DIAGNOSTIC TESTS, BY COUNTRY, 2018–2020 (USD MILLION)

TABLE 39 EUROPE: HEPATITIS TESTING MARKET FOR RAPID DIAGNOSTIC TESTS, BY COUNTRY, 2021–2026 (USD MILLION)

7.4 POLYMERASE CHAIN REACTION (PCR)

7.4.1 PCR TECHNOLOGY IS USED IN CONFIRMATORY TESTS FOR HEPATITIS DIAGNOSIS

TABLE 40 HEPATITIS TESTING MARKET FOR POLYMERASE CHAIN REACTION, BY REGION, 2018–2020 (USD MILLION)

TABLE 41 HEPATITIS TESTING MARKET FOR POLYMERASE CHAIN REACTION, BY REGION, 2021–2026 (USD MILLION)

TABLE 42 NORTH AMERICA: HEPATITIS TESTING MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2018–2020 (USD MILLION)

TABLE 43 NORTH AMERICA: HEPATITIS TESTING MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2021–2026 (USD MILLION)

TABLE 44 EUROPE: HEPATITIS TESTING MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2018–2020 (USD MILLION)

TABLE 45 EUROPE: HEPATITIS TESTING MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2021–2026 (USD MILLION)

7.5 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY (INAAT)

7.5.1 COST-BENEFITS OF INAAT ARE DRIVING THE GROWTH OF THIS MARKET SEGMENT

TABLE 46 HEPATITIS TESTING MARKET FOR INAAT, BY REGION, 2018–2020 (USD MILLION)

TABLE 47 HEPATITIS TESTING MARKET FOR INAAT, BY REGION, 2021–2026 (USD MILLION)

TABLE 48 NORTH AMERICA: HEPATITIS TESTING MARKET FOR INAAT, BY COUNTRY, 2018–2020 (USD MILLION)

TABLE 49 NORTH AMERICA: HEPATITIS TESTING MARKET FOR INAAT, BY COUNTRY, 2021–2026 (USD MILLION)

TABLE 50 EUROPE: HEPATITIS TESTING MARKET FOR INAAT, BY COUNTRY, 2018–2020 (USD MILLION)

TABLE 51 EUROPE: HEPATITIS TESTING MARKET FOR INAAT, BY COUNTRY, 2021–2026 (USD MILLION)

7.6 OTHER TECHNOLOGIES

TABLE 52 HEPATITIS TESTING MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2018–2020 (USD MILLION)

TABLE 53 HEPATITIS TESTING MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2021–2026 (USD MILLION)

TABLE 54 NORTH AMERICA: HEPATITIS TESTING MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2018–2020 (USD MILLION)

TABLE 55 NORTH AMERICA: HEPATITIS TESTING MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2021–2026 (USD MILLION)

TABLE 56 EUROPE: HEPATITIS TESTING MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2018–2020 (USD MILLION)

TABLE 57 EUROPE: HEPATITIS TESTING MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2021–2026 (USD MILLION)

8 HEPATITIS TESTING MARKET, BY END USER

8.1 INTRODUCTION

TABLE 58 HEPATITIS TESTING MARKET, BY END USER, 2018–2020 (USD

MILLION)

TABLE 59 HEPATITIS TESTING MARKET, BY END USER, 2021–2026 (USD MILLION)

8.2 HOSPITAL & DIAGNOSTIC LABORATORIES

8.2.1 HOSPITAL & DIAGNOSTIC LABORATORIES ARE THE LARGEST END USERS

OF HEPATITIS TESTING PRODUCTS

TABLE 60 HEPATITIS TESTING MARKET FOR HOSPITAL & DIAGNOSTIC LABORATORIES, BY REGION, 2018–2020 (USD MILLION)

TABLE 61 HEPATITIS TESTING MARKET FOR HOSPITAL & DIAGNOSTIC LABORATORIES, BY REGION, 2021–2026 (USD MILLION)

TABLE 62 NORTH AMERICA: HEPATITIS TESTING MARKET FOR HOSPITAL & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018–2020 (USD MILLION)

TABLE 63 NORTH AMERICA: HEPATITIS TESTING MARKET FOR HOSPITAL & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2021–2026 (USD MILLION)

TABLE 64 EUROPE: HEPATITIS TESTING MARKET FOR HOSPITAL & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018–2020 (USD MILLION)

TABLE 65 EUROPE: HEPATITIS TESTING MARKET FOR HOSPITAL & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2021–2026 (USD MILLION)

8.3 BLOOD BANKS

8.3.1 INCREASING NUMBER OF BLOOD DONATIONS TO DRIVE THE GROWTH OF THIS MARKET SEGMENT

TABLE 66 HEPATITIS TESTING MARKET FOR BLOOD BANKS, BY REGION, 2018–2020 (USD MILLION)

TABLE 67 HEPATITIS TESTING MARKET FOR BLOOD BANKS, BY REGION, 2021–2026 (USD MILLION)

TABLE 68 NORTH AMERICA: HEPATITIS TESTING MARKET FOR BLOOD BANKS, BY COUNTRY, 2018–2020 (USD MILLION)

TABLE 69 NORTH AMERICA: HEPATITIS TESTING MARKET FOR BLOOD BANKS, BY COUNTRY, 2021–2026 (USD MILLION)

TABLE 70 EUROPE: HEPATITIS TESTING MARKET FOR BLOOD BANKS, BY COUNTRY, 2018–2020 (USD MILLION)

TABLE 71 EUROPE: HEPATITIS TESTING MARKET FOR BLOOD BANKS, BY COUNTRY, 2021–2026 (USD MILLION)

8.4 OTHER END USERS

TABLE 72 HEPATITIS TESTING MARKET FOR OTHER END USERS, BY REGION, 2018–2020 (USD MILLION)

TABLE 73 HEPATITIS TESTING MARKET FOR OTHER END USERS, BY REGION, 2021–2026 (USD MILLION)

TABLE 74 NORTH AMERICA: HEPATITIS TESTING MARKET FOR OTHER END USERS, BY COUNTRY, 2018–2020 (USD MILLION)

TABLE 75 NORTH AMERICA: HEPATITIS TESTING MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2026 (USD MILLION)

TABLE 76 EUROPE: HEPATITIS TESTING MARKET FOR OTHER END USERS, BY COUNTRY, 2018–2020 (USD MILLION)

TABLE 77 EUROPE: HEPATITIS TESTING MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2026 (USD MILLION)

9 HEPATITIS TESTING MARKET, BY REGION

9.1 INTRODUCTION

TABLE 78 GLOBAL: HEPATITIS TESTING MARKET, BY REGION, 2018–2020 (USD MILLION)

TABLE 79 GLOBAL: HEPATITIS TESTING MARKET, BY REGION, 2021–2026 (USD MILLION)

9.2 NORTH AMERICA

FIGURE 20 NORTH AMERICA: HEPATITIS TESTING MARKET SNAPSHOT

TABLE 80 NORTH AMERICA: HEPATITIS TESTING MARKET, BY COUNTRY, 2018–2020 (USD MILLION)

TABLE 81 NORTH AMERICA: HEPATITIS TESTING MARKET, BY COUNTRY, 2021–2026 (USD MILLION)

TABLE 82 NORTH AMERICA: HEPATITIS TESTING MARKET, BY DISEASE TYPE, 2018–2020 (USD MILLION)

TABLE 83 NORTH AMERICA: HEPATITIS TESTING MARKET, BY DISEASE TYPE, 2021–2026 (USD MILLION)

TABLE 84 NORTH AMERICA: HEPATITIS TESTING MARKET, BY TECHNOLOGY, 2018–2020 (USD MILLION)

TABLE 85 NORTH AMERICA: HEPATITIS TESTING MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)

TABLE 86 NORTH AMERICA: HEPATITIS TESTING MARKET, BY END USER, 2018–2020 (USD MILLION)

TABLE 87 NORTH AMERICA: HEPATITIS TESTING MARKET, BY END USER, 2021–2026 (USD MILLION)

9.2.1 US

9.2.1.1 High healthcare expenditure to drive market growth in the US

TABLE 88 US: NUMBER OF HEPATITIS A CASES REPORTED, 2015 VS. 2019

TABLE 89 HEPATITIS A PREVALENCE RATE PER 100,000 POPULATION IN THE US, 2013–2017

TABLE 90 US: KEY MACROINDICATORS

TABLE 91 US: HEPATITIS TESTING MARKET, BY DISEASE TYPE, 2018–2020 (USD MILLION)

TABLE 92 US: HEPATITIS TESTING MARKET, BY DISEASE TYPE, 2021–2026 (USD MILLION)

TABLE 93 US: HEPATITIS TESTING MARKET, BY TECHNOLOGY, 2018–2020 (USD MILLION)

TABLE 94 US: HEPATITIS TESTING MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)

TABLE 95 US: HEPATITIS TESTING MARKET, BY END USER, 2018–2020 (USD MILLION)

TABLE 96 US: HEPATITIS TESTING MARKET, BY END USER, 2021–2026 (USD MILLION)

9.2.2 CANADA

9.2.2.1 Favorable government initiatives are expected to boost market growth in Canada

TABLE 97 CANADA: KEY MACROINDICATORS

TABLE 98 CANADA: HEPATITIS TESTING MARKET, BY DISEASE TYPE, 2018–2020 (USD MILLION)

TABLE 99 CANADA: HEPATITIS TESTING MARKET, BY DISEASE TYPE, 2021–2026 (USD MILLION)

TABLE 100 CANADA: HEPATITIS TESTING MARKET, BY TECHNOLOGY, 2018–2020 (USD MILLION)

TABLE 101 CANADA: HEPATITIS TESTING MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)

TABLE 102 CANADA: HEPATITIS TESTING MARKET, BY END USER, 2018–2020 (USD MILLION)

TABLE 103 CANADA: HEPATITIS TESTING MARKET, BY END USER, 2021–2026 (USD MILLION)

9.3 EUROPE

TABLE 104 NUMBER OF HEPATITIS B CASES IN EUROPE, BY COUNTRY, 2014–2018

TABLE 105 EUROPE: HEPATITIS TESTING MARKET, BY COUNTRY, 2018–2020 (USD MILLION)

TABLE 106 EUROPE: HEPATITIS TESTING MARKET, BY COUNTRY, 2021–2026 (USD MILLION)

TABLE 107 EUROPE: HEPATITIS TESTING MARKET, BY DISEASE TYPE, 2018–2020 (USD MILLION)

TABLE 108 EUROPE: HEPATITIS TESTING MARKET, BY DISEASE TYPE,

2021–2026 (USD MILLION)

TABLE 109 EUROPE: HEPATITIS TESTING MARKET, BY TECHNOLOGY,
2018–2020 (USD MILLION)

TABLE 110 EUROPE: HEPATITIS TESTING MARKET, BY TECHNOLOGY,
2021–2026 (USD MILLION)

TABLE 111 EUROPE: HEPATITIS TESTING MARKET, BY END USER, 2018–2020
(USD MILLION)

TABLE 112 EUROPE: HEPATITIS TESTING MARKET, BY END USER, 2021–2026
(USD MILLION)

9.3.1 GERMANY

9.3.1.1 Increasing demand for advanced diagnostic technologies to drive market
growth in Germany

TABLE 113 GERMANY: KEY MACROINDICATORS

TABLE 114 GERMANY: HEPATITIS TESTING MARKET, BY DISEASE TYPE,
2018–2020 (USD MILLION)

TABLE 115 GERMANY: HEPATITIS TESTING MARKET, BY DISEASE TYPE,
2021–2026 (USD MILLION)

TABLE 116 GERMANY: HEPATITIS TESTING MARKET, BY TECHNOLOGY,
2018–2020 (USD MILLION)

TABLE 117 GERMANY: HEPATITIS TESTING MARKET, BY TECHNOLOGY,
2021–2026 (USD MILLION)

TABLE 118 GERMANY: HEPATITIS TESTING MARKET, BY END USER, 2018–2020
(USD MILLION)

TABLE 119 GERMANY: HEPATITIS TESTING MARKET, BY END USER, 2021–2026
(USD MILLION)

9.3.2 UK

9.3.2.1 Increasing number of clinical laboratories to drive market
growth in the UK

TABLE 120 NUMBER OF HEPATITIS C CASES REPORTED IN ENGLAND AND
WALES, 2008–2018

TABLE 121 UK: KEY MACROINDICATORS

TABLE 122 UK: HEPATITIS TESTING MARKET, BY DISEASE TYPE, 2018–2020
(USD MILLION)

TABLE 123 UK: HEPATITIS TESTING MARKET, BY DISEASE TYPE, 2021–2026
(USD MILLION)

TABLE 124 UK: HEPATITIS TESTING MARKET, BY TECHNOLOGY, 2018–2020 (USD
MILLION)

TABLE 125 UK: HEPATITIS TESTING MARKET, BY TECHNOLOGY, 2021–2026 (USD
MILLION)

TABLE 126 UK: HEPATITIS TESTING MARKET, BY END USER, 2018–2020 (USD MILLION)

TABLE 127 UK: HEPATITIS TESTING MARKET, BY END USER, 2021–2026 (USD MILLION)

9.3.3 REST OF EUROPE

TABLE 128 ROE: HEALTHCARE EXPENDITURE, BY COUNTRY, 2010 VS. 2018 (% OF GDP)

TABLE 129 ROE: HEPATITIS TESTING MARKET, BY DISEASE TYPE, 2018–2020 (USD MILLION)

TABLE 130 ROE: HEPATITIS TESTING MARKET, BY DISEASE TYPE, 2021–2026 (USD MILLION)

TABLE 131 ROE: HEPATITIS TESTING MARKET, BY TECHNOLOGY, 2018–2020 (USD MILLION)

TABLE 132 ROE: HEPATITIS TESTING MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)

TABLE 133 ROE: HEPATITIS TESTING MARKET, BY END USER, 2018–2020 (USD MILLION)

TABLE 134 ROE: HEPATITIS TESTING MARKET, BY END USER, 2021–2026 (USD MILLION)

9.4 ASIA PACIFIC

9.4.1 HIGH PREVALENCE OF HEPATITIS TO BOOST MARKET GROWTH

TABLE 135 ASIA PACIFIC: ESTIMATED PREVALENCE OF CHRONIC HBV AND HCV

TABLE 136 ASIA PACIFIC: COST COVERAGE FOR THE DIAGNOSIS OF CHRONIC VIRAL HEPATITIS

FIGURE 21 ASIA PACIFIC: HEPATITIS TESTING MARKET SNAPSHOT

TABLE 137 CHINA: KEY MACROINDICATORS

TABLE 138 JAPAN: KEY MACROINDICATORS

TABLE 139 INDIA: KEY MACROINDICATORS

TABLE 140 ASIA PACIFIC: HEPATITIS TESTING MARKET, BY DISEASE TYPE, 2018–2020 (USD MILLION)

TABLE 141 ASIA PACIFIC: HEPATITIS TESTING MARKET, BY DISEASE TYPE, 2021–2026 (USD MILLION)

TABLE 142 ASIA PACIFIC: HEPATITIS TESTING MARKET, BY TECHNOLOGY, 2018–2020 (USD MILLION)

TABLE 143 ASIA PACIFIC: HEPATITIS TESTING MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)

TABLE 144 ASIA PACIFIC: HEPATITIS TESTING MARKET, BY END USER, 2018–2020 (USD MILLION)

TABLE 145 ASIA PACIFIC: HEPATITIS TESTING MARKET, BY END USER,

2021–2026 (USD MILLION)

9.5 REST OF THE WORLD

9.5.1 LESS-STRINGENT REGULATIONS FOR DIAGNOSTIC PRODUCTS TO DRIVE MARKET GROWTH

TABLE 146 REST OF THE WORLD: HEPATITIS TESTING MARKET, BY DISEASE TYPE, 2018–2020 (USD MILLION)

TABLE 147 REST OF THE WORLD: HEPATITIS TESTING MARKET, BY DISEASE TYPE, 2021–2026 (USD MILLION)

TABLE 148 REST OF THE WORLD: HEPATITIS TESTING MARKET, BY TECHNOLOGY, 2018–2020 (USD MILLION)

TABLE 149 REST OF THE WORLD: HEPATITIS TESTING MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)

TABLE 150 REST OF THE WORLD: HEPATITIS TESTING MARKET, BY END USER, 2018–2020 (USD MILLION)

TABLE 151 REST OF THE WORLD: HEPATITIS TESTING MARKET, BY END USER, 2021–2026 (USD MILLION)

10 COMPETITIVE LANDSCAPE

10.1 OVERVIEW

10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN

TABLE 152 OVERVIEW OF STRATEGIES ADOPTED BY KEY HEPATITIS TESTING MARKET PLAYERS

10.3 MARKET SHARE ANALYSIS

FIGURE 22 HEPATITIS TESTING MARKET SHARE ANALYSIS, 2020

TABLE 153 HEPATITIS TESTING MARKET: DEGREE OF COMPETITION (2020)

10.4 COMPANY EVALUATION QUADRANT

10.4.1 STARS

10.4.2 EMERGING LEADERS

10.4.3 PERVASIVE PLAYERS

10.4.4 PARTICIPANTS

FIGURE 23 HEPATITIS TESTING MARKET: COMPANY EVALUATION QUADRANT (2020)

10.5 COMPANY EVALUATION QUADRANT: SMES/START-UPS

10.5.1 PROGRESSIVE COMPANIES

10.5.2 STARTING BLOCKS

10.5.3 RESPONSIVE COMPANIES

10.5.4 DYNAMIC COMPANIES

FIGURE 24 HEPATITIS TESTING MARKET: COMPANY EVALUATION QUADRANT

FOR SMES & START-UPS (2020)**10.6 COMPETITIVE SCENARIO****10.6.1 PRODUCT LAUNCHES & APPROVALS****TABLE 154 PRODUCT LAUNCHES & APPROVALS****10.6.2 DEALS****TABLE 155 DEALS****10.6.3 OTHER DEVELOPMENTS****TABLE 156 OTHER DEVELOPMENTS****10.7 COMPANY FOOTPRINT ANALYSIS****TABLE 157 TECHNOLOGY, DISEASE TYPE, AND REGIONAL FOOTPRINT OF COMPANIES****TABLE 158 TECHNOLOGY FOOTPRINT OF COMPANIES****TABLE 159 DISEASE TYPE FOOTPRINT OF COMPANIES****TABLE 160 REGIONAL FOOTPRINT OF COMPANIES****11 COMPANY PROFILE****11.1 KEY PLAYERS**

(Business Overview, Products Offered, Recent Developments, Deals, MnM view, Key strengths/right to win, Strategic choices made, Weakness/competitive threats)*

11.1.1 ABBOTT LABORATORIES**TABLE 161 ABBOTT LABORATORIES: BUSINESS OVERVIEW****FIGURE 25 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2020)****11.1.2 F. HOFFMANN-LA ROCHE LTD.****TABLE 162 F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW****FIGURE 26 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2020)****11.1.3 BIO-RAD LABORATORIES, INC.****TABLE 163 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW****FIGURE 27 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2020)****11.1.4 SIEMENS HEALTHINEERS AG****TABLE 164 SIEMENS HEALTHINEERS AG: BUSINESS OVERVIEW****FIGURE 28 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2020)****11.1.5 DIASORIN S.P.A****TABLE 165 DIASORIN S.P.A: BUSINESS OVERVIEW****FIGURE 29 DIASORIN S.P.A.: COMPANY SNAPSHOT (2020)****11.1.6 QIAGEN****TABLE 166 QIAGEN: BUSINESS OVERVIEW****FIGURE 30 QIAGEN: COMPANY SNAPSHOT (2020)****11.1.7 DANAHER CORPORATION**

TABLE 167 DANAHER CORPORATION: BUSINESS OVERVIEW

FIGURE 31 DANAHER CORPORATION: COMPANY SNAPSHOT (2020)

11.1.8 GRIFOLS, S.A.

TABLE 168 GRIFOLS, S.A.: BUSINESS OVERVIEW

FIGURE 32 GRIFOLS, S.A.: COMPANY SNAPSHOT (2020)

11.1.9 BIOM?RIEUX SA

TABLE 169 BIOM?RIEUX SA: BUSINESS OVERVIEW

FIGURE 33 BIOM?RIEUX SA: COMPANY SNAPSHOT (2020)

11.1.10 ORTHO CLINICAL DIAGNOSTICS

TABLE 170 ORTHO CLINICAL DIAGNOSTICS: BUSINESS OVERVIEW

FIGURE 34 ORTHO CLINICAL DIAGNOSTICS: COMPANY SNAPSHOT (2020)

11.2 OTHER PLAYERS

11.2.1 FUJIREBIO US, INC.

11.2.2 ORASURE TECHNOLOGIES

11.2.3 EPI TOPE DIAGNOSTICS

11.2.4 TRIVITRON HEALTHCARE

11.2.5 MERIL LIFE SCIENCES PVT. LTD.

11.2.6 GENMARK DIAGNOSTICS INC.

11.2.7 VELA DIAGNOSTICS

11.2.8 MOLBIO DIAGNOSTICS PVT. LTD.

11.2.9 GENEOMBIO TECHNOLOGIES PVT. LTD.

11.2.10 MEDMIRA INC.

*Details on Business Overview, Products Offered, Recent Developments, Deals, MnM view, Key strengths/right to win, Strategic choices made, Weakness/competitive threats might not be captured in case of unlisted companies.

12 APPENDIX

12.1 INSIGHTS FROM INDUSTRY EXPERTS

12.2 DISCUSSION GUIDE

12.3 KNOWLEDGE STORE: MARKETSandMARKETS' SUBSCRIPTION PORTAL

12.4 AVAILABLE CUSTOMIZATIONS

12.5 RELATED REPORTS

12.6 AUTHOR DETAILS

I would like to order

Product name: Hepatitis Testing/Diagnosis Market by Disease Type (Hepatitis B, Hepatitis C, Other Hepatitis), Technology (ELISA, RDT, PCR, INAAT), End User (Hospitals, Diagnostic Laboratories, Blood Banks), and Region - Global Forecast to 2026

Product link: <https://marketpublishers.com/r/H234F687B2EEN.html>

Price: US\$ 4,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/H234F687B2EEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970